The European Commission visits REIG JOFRE’s Barcelona plant as part of its vaccine manufacturing strategy
- The European Commission visits REIG JOFRE’s Barcelona plant, designated as an operator within the EU FAB program.
- The company strengthens its role in Europe’s health autonomy and next-generation vaccine production.
- The consortium with Zendal group ensures rapid response capacity to future public health emergencies.
REIG JOFRE, (BME:RJF), a pharmaceutical company listed on the Spanish Stock Exchange, welcomed a delegation from the European Commission to its Barcelona plant. The visit was led by Mr. Csaba Gáli, Deputy Head of Unit Medical Counter-Measures at the European Health Emergency Preparedness and Response Authority (HERA), and Laura Rahola, Communication Officer at the European Commission’s Representation in Barcelona.
The visit took place within the framework of the agreement signed between the consortium formed by REIG JOFRE and the biotech company CZ Vaccines (a subsidiary of Zendal Group) with the European Commission, aimed at ensuring Europe’s vaccine manufacturing capacity in the face of future health emergencies.
The European delegation was received by Ignasi Biosca, CEO of REIG JOFRE, accompanied by Zenadal’s Global Marketing and Sales Director, Pascual Rey, together with other members of the host company. During the meeting, they highlighted the relevance of this strategic collaboration in strengthening Europe’s preparedness for potential health crises, while also emphasizing the close coordination and mutual trust between both organizations, which work as a single team under the EU FAB framework, sharing responsibilities and common objectives.
During the visit, participants toured REIG JOFRE’s aseptic production plant in Barcelona, designated as an operator within the European EU FAB program, for the reservation of specific vaccine manufacturing capacities to enable a rapid response to health emergencies and ensure the supply of the necessary vaccines for the European population. This facility is one of the most advanced in Europe and represents a strategic asset within the EU pharmaceutical ecosystem.
The plant is equipped with state-of-the-art isolator technology, automated and robotized systems, and is designed to produce injectable medicines, including mRNA vaccines, viral vectors, recombinant proteins, and other biological treatments. With an annual capacity of 45 million lyophilized vials and 50 million liquid vials, it strengthens REIG JOFRE’s position among international leaders in high-complexity pharmaceutical manufacturing.